Model Role Details

Adnan Mjalli

Adnan Mjalli

Sector : Academic Figures , Doctors

Personal Info

  • Country of residence : United States
  • Gender : Male
  • Born in : 1963
  • Age : 48
  • Curriculum vitae :

Information

Adnan Mjalli obtained his Ph.D. in medicinal chemistry in 1989 from the University of Exeter, UK. His postdoctoral work was carried out at the University of Rochester. Dr. Mjalli is an internationally recognized expert in drug discovery and development in the pharmaceutical and biotechnology industry. He held various positions of increasing responsibility in research and senior management at several pharmaceutical and biotechnology companies including Merck & Co. He is the author of more than 40 scientific papers, 30 patents and four book chapters.

He currently serves as Chairman of the Board of PharmaCore, a company he also founded in 1998. He previously served as President and CEO of PharmaCore from December of 1998 to November 2000. Dr. Mjalli also serves on the Board of Directors of Siga Technologies, Inc., a biopharmaceuticals company developing products for the prevention and treatment of serious infectious diseases and biowarfare agents. He serves on the Board of Directors for the North Carolina Biotechnology Center located in Research Triangle Park, NC, and on the Advisory Committee for Biotechnology in the Piedmont Triad. Dr. Mjalli is the founder of TransTech Pharma,Inc.

Mjalli spent the first year developing his business plan, talking to potential investors and interviewing prospective employees. He chose to locate the company in North Carolina because of the advances it was making in attracting new pharmaceutical and biotechnology businesses; however, he bypassed Research Triangle Park and instead established TransTech in the Triad region of North Carolina. Mjalli was able to secure funding of over $110 million in equity as well as revenues generated from multimillion drug discovery and development collaborations with large pharmaceutical companies such as Novo Nordisk, Merck, Boehringer Ingelheim, Cephalon and Pfizer. TransTech has eight clinical and 11 preclinical programs directed at treating Alzheimer’s disease, diabetes, obesity, cancer, pain and inflammation.

Achievements and Awards

Dr. Mjalli has been the recipient of several awards and honors including: the 2007 Fast 50 Award honoring the Triads 50 fastest growing private companies and their CEOs, Carolinas regional Finalist for Ernst & Young 2007 Entrepreneur of the Year, the Health Care Heroes Innovator Award and the North Carolina Biotechnology Economic Development Award from the North Carolina Biotechnology Center. He has been named among the Triads Most Influential People, was issued the City of High Point North Carolina Key Award and awarded the Science Award in Recognition and Appreciation of Excellence in Innovation and Creativity by Helios Pharmaceuticals. As a student, he was the recipient of academic awards such as the Glaxo Group Research Scholarship for Ph.D. degree, the Lovis Rydon Memorial Research Prize for Outstanding Research from the University of Exeter and the European Economic Community Scholarship for M.S. degree.

  • Marital status :
  • City :
  • Status :
  • Years in active : From To